Dr. Domchek on the MEDIOLA Trial in Breast Cancer

Susan Domchek, MD
Published: Tuesday, Dec 19, 2017



Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the MEDIOLA trial in breast cancer.

During the 2017 San Antonio Breast Cancer Symposium, the results of the first 25 patients with BRCA1/2-mutated metastatic breast cancer treated with olaparib (Lynparza) and durvalumab (Imfinzi) from the MEDIOLA trial were presented.

Results showed an 80% clinical benefit rate at 12 weeks, suggesting that this is an active combination in this population. The impact of durvalumab is still unknown, says Domchek, as olaparib has shown benefit as a single-agent in this population.
SELECTED
LANGUAGE


Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses the MEDIOLA trial in breast cancer.

During the 2017 San Antonio Breast Cancer Symposium, the results of the first 25 patients with BRCA1/2-mutated metastatic breast cancer treated with olaparib (Lynparza) and durvalumab (Imfinzi) from the MEDIOLA trial were presented.

Results showed an 80% clinical benefit rate at 12 weeks, suggesting that this is an active combination in this population. The impact of durvalumab is still unknown, says Domchek, as olaparib has shown benefit as a single-agent in this population.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x